View:
OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden hours per response 11.00
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
Lifeline Therapeutics, Inc.
-----------------------------------------------
(Name of Issuer)
Common Stock
---------------------------------------------------------
(Title of Class of Securities)
53221T108
-----------------------------
(CUSIP Number)
Joe McCord
390 South Hudson Street
Unit 6
Denver, CO 80246
Telephone: 720 488 1711
---------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 26, 2004
------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box [ ].
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Section 240.13d-7 for other
parties to whom copies are to be sent.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes)
SCHEDULE 13D
CUSIP No. 53221T108 Page 2 of 4
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON. I.R.S. IDENTIFICATION NO.OF ABOVE PERSON
Joe McCord
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS
PF
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------------------------------------------------------------------
NUMBER OF | 7 | SOLE VOTING POWER
SHARES 1,606,800 shares
BENEFICIALLY -----------------------------------------------------
OWNED BY | 8 | SHARED VOTING POWER
EACH 0 shares
REPORTING -----------------------------------------------------
PERSON | 9 | SOLE DISPOSITIVE POWER
WITH 1,606,800 shares
-----------------------------------------------------
| 10 | SHARED DISPOSITIVE POWER
0 shares
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,606,800 shares
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES [ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.8 %
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
SCHEDULE 13D
CUSIP No. 53221T108 Page 3 of 4
- --------------------------------------------------------------------------------
Item 1. Security And Issuer
This Statement relates to the Common Stock of Lifeline Therapeutics, Inc.,
a company organized under the laws of the State of Colorado. The principal
executive offices of the Company are located at 6400 South Fiddlers Green
Circle, Suite 1750, Englewood, Colorado 80111.
Item 2. Identity and Background
The identity and business address of the reporting person is Joe McCord,
390 South Hudson Street, Unit 6, Denver CO 80246.
The reporting person serves as the Director of Science of Lifeline
Nutraceuticals Corporation, 6400 South Fiddlers Green Circle, Suite 1750,
Englewood, CO 80111.
The reporting person has not been convicted in a criminal proceeding of the
nature described in Item 2(d) of Schedule 13D in the last five years. The
reporting person has not been a party to a civil proceeding of the nature
described in Item 2(e) of Schedule 13D in the last five years.
The reporting person is a citizen of the United States.
Item 3. Source and Amount of Funds or Other Consideration
This Schedule 13D reports the following transactions:
- -------------------------------------- -----------------------------------------
Securities Amount/Source of Funds
- -------------------------------------- -----------------------------------------
1,606,800 On October 26, 2004, the reporting person
shares of common stock acquired the shares of common stock
pursuant to the terms of an Agreement and
Plan of Reorganization between Lifeline
Nutraceuticals Corporation and Lifeline
Therapeutics, Inc., whereby the
shareholders of Lifeline Nutraceuticals
exchanged their outstanding common stock
in Lifeline Nutraceuticals for newly
issued stock in Lifeline Therapeutics,
Inc.
- -------------------------------------- -----------------------------------------
Item 4. Purpose of Transaction
The reporting person acquired these shares for investment purposes.
SCHEDULE 13D
CUSIP No. 53221T108 Page 4 of 4
- --------------------------------------------------------------------------------
Item 5. Interest in the Securities of the Issuer
(a) The reporting person's aggregate interest and percentage of common
stock of Lifeline Therapeutics, Inc. equals 1,606,800 shares (9.8% of the shares
of common stock outstanding). The shares of common stock described above are the
only interest the reporting person has in Lifeline Therapeutics, Inc. common
stock.
(b) The reporting person has sole voting and sole dispositive power with
respect to 1,606,800 shares of common stock. The reporting person does not have
shared voting and dispositive power with respect to any shares of common stock
of Lifeline Therapeutics, Inc.
(c) N/A
(d) N/A
(e) N/A
Item 6. Contract, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer
None
Item 7. Material to be Filed as Exhibits
N/A
Signature:
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: December 28, 2004 By: /s/ Joe McCord
------------------------------
ATTENTION: Intentional misstatements or omissions of fact constitute
federal criminal violations. (See 18USC1001)